001     271226
005     20240229154923.0
024 7 _ |a 10.1016/j.ajcnut.2022.10.004
|2 doi
024 7 _ |a pmid:36789942
|2 pmid
024 7 _ |a 0095-9871
|2 ISSN
024 7 _ |a 0002-9165
|2 ISSN
024 7 _ |a 1938-3207
|2 ISSN
024 7 _ |a 1938-3215
|2 ISSN
024 7 _ |a altmetric:142614711
|2 altmetric
037 _ _ |a DKFZ-2023-00363
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Karavasiloglou, Nena
|b 0
245 _ _ |a Prediagnostic serum calcium concentrations and risk of colorectal cancer development in 2 large European prospective cohorts.
260 _ _ |a Oxford
|c 2023
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1676976374_21826
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Higher dietary calcium consumption is associated with lower colorectal cancer (CRC) risk. However, little data are available on the association between circulating calcium concentrations and CRC risk.To explore the association between circulating calcium concentrations and CRC risk using data from 2 large European prospective cohort studies.Conditional logistic regression models were used to calculate multivariable-adjusted ORs and 95% CIs in case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC; n-cases = 947, n-controls = 947) and the UK Biobank (UK-BB; n-cases = 2759, n-controls = 12,021) cohorts.In EPIC, nonalbumin-adjusted total serum calcium (a proxy of free calcium) was not associated with CRC (OR: 0.94; 95% CI: 0.85, 1.03; modeled as continuous variable, per 1 mg/dL increase), colon cancer (OR: 0.93; 95% CI: 0.82, 1.05) or rectal cancer (OR: 1.01; 95% CI: 0.84, 1.20) risk in the multivariable adjusted model. In the UK-BB, serum ionized calcium (free calcium, most active form) was inversely associated with the risk of CRC (OR: 0.85; 95% CI: 0.76, 0.95; per 1 mg/dL) and colon cancer (OR: 0.78; 95% CI: 0.68, 0.90), but not rectal cancer (OR: 1.02; 95% CI: 0.83, 1.24) in multivariable adjusted models. Meta-analysis of EPIC and UK-BB CRC risk estimates showed an inverse risk association for CRC in the multivariable adjusted model (OR: 0.90; 95%CI: 0.84, 0.97). In analyses by quintiles, in both cohorts, higher levels of serum calcium were associated with reduced CRC risk (EPIC: ORQ5vs.Q1: 0.69; 95% CI: 0.47, 1.00; P-trend = 0.03; UK-BB: ORQ5vs.Q1: 0.82; 95% CI: 0.72, 0.94; P-trend < 0.01). Analyses by anatomical subsite showed an inverse cancer risk association in the colon (EPIC: ORQ5vs.Q1: 0.63, 95% CI: 0.39, 1.02; P-trend = 0.05; UK-BB: ORQ5vs.Q1: 0.75; 95% CI: 0.64, 0.88; P-trend < 0.01) but not the rectum.In UK-BB, higher serum ionized calcium levels were inversely associated with CRC, but the risk was restricted to the colon. Total serum calcium showed a null association in EPIC. Additional prospective studies in other populations are needed to better investigate these associations.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a cancer
|2 Other
650 _ 7 |a cohort
|2 Other
650 _ 7 |a colorectal
|2 Other
650 _ 7 |a risk
|2 Other
650 _ 7 |a serum calcium
|2 Other
650 _ 7 |a Calcium
|0 SY7Q814VUP
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Calcium
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: etiology
|2 MeSH
650 _ 2 |a Nutritional Status
|2 MeSH
650 _ 2 |a Colonic Neoplasms
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Europe: epidemiology
|2 MeSH
700 1 _ |a Hughes, David J
|b 1
700 1 _ |a Murphy, Neil
|b 2
700 1 _ |a Schomburg, Lutz
|b 3
700 1 _ |a Sun, Qian
|b 4
700 1 _ |a Seher, Vartiter
|b 5
700 1 _ |a Rohrmann, Sabine
|b 6
700 1 _ |a Weiderpass, Elisabete
|b 7
700 1 _ |a Tjønneland, Anne
|b 8
700 1 _ |a Olsen, Anja
|b 9
700 1 _ |a Overvad, Kim
|b 10
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 11
700 1 _ |a Mancini, Francesca Romana
|b 12
700 1 _ |a Mahamat-Saleh, Yahya
|b 13
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 14
|u dkfz
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 15
700 1 _ |a Schulze, Matthias B
|b 16
700 1 _ |a Tumino, Rosario
|b 17
700 1 _ |a Panico, Salvatore
|b 18
700 1 _ |a Masala, Giovanna
|b 19
700 1 _ |a Pala, Valeria
|b 20
700 1 _ |a Sacerdote, Carlotta
|b 21
700 1 _ |a Derksen, Jeroen W G
|b 22
700 1 _ |a Skeie, Guri
|b 23
700 1 _ |a Hjartåker, Anette
|b 24
700 1 _ |a Lasheras, Cristina
|b 25
700 1 _ |a Agudo, Antonio
|b 26
700 1 _ |a Sánchez, Maria-José
|b 27
700 1 _ |a Chirlaque, Maria-Dolores
|b 28
700 1 _ |a Ardanaz, Eva
|b 29
700 1 _ |a Amiano, Pilar
|b 30
700 1 _ |a Van Guelpen, Bethany
|b 31
700 1 _ |a Gylling, Björn
|b 32
700 1 _ |a Bradbury, Kathryn E
|b 33
700 1 _ |a Papier, Keren
|b 34
700 1 _ |a Freisling, Heinz
|b 35
700 1 _ |a Aglago, Elom K
|b 36
700 1 _ |a Cross, Amanda J
|b 37
700 1 _ |a Riboli, Elio
|b 38
700 1 _ |a Aune, Dagfinn
|b 39
700 1 _ |a Gunter, Marc J
|b 40
700 1 _ |a Jenab, Mazda
|b 41
773 _ _ |a 10.1016/j.ajcnut.2022.10.004
|g Vol. 117, no. 1, p. 33 - 45
|0 PERI:(DE-600)1496439-9
|n 1
|p 33 - 45
|t The American journal of clinical nutrition
|v 117
|y 2023
|x 0095-9871
909 C O |o oai:inrepo02.dkfz.de:271226
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J CLIN NUTR : 2022
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b AM J CLIN NUTR : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21